Answers are grounded in this paper and cite their sources.
Randomized trial evaluates fasting-mimicking diet with pembrolizumab in veterans with advanced lung cancer, indicating potential benefits.
TPS8666 Background: Single-agent PD-(L)1 inhibitors are standard first-line therapy for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%, yielding objective response rates of approximately 45% and median overall survival of 20-26 months. However, immune-related adverse events (irAEs) occur in up to 20% of patients. Fasting-mimicking diets (FMD) induce metabolic reprogramming by reducing insulin-like growth factor 1 (IGF-1) and glucose while increasing IGF-binding protein 1. Preclinical data demonstrate that FMD enhances anti-tumor immunity by increasing T-cell mediated tumor cytotoxicity, reducing myeloid-derived suppressor cells, and suppressing T-regulatory cell function. Recent murine models show that FMD combined with anti-PD-L1 therapy prevents or reverses immune-mediated myocardial infiltration, reduces systemic inflammation, and is more effective than anti-PD-L1 alone in delaying tumor growth while reshaping the tumor microenvironment. Our prior feasibility study (IUSCCC-0662) in 10 advanced lung cancer patients demonstrated 80% compliance with FMD, with minimal toxicities. These findings suggest FMD may enhance checkpoint inhibitor efficacy while potentially reducing irAEs. Methods: This is an open-label, randomized pilot study evaluating the feasibility and safety of FMD combined with pembrolizumab in Veterans with newly diagnosed stage IV NSCLC and PD-L1 expression ≥50%. Eligible patients must have ECOG performance status 0-2 and adequate organ function. Patients receive pembrolizumab 200 mg IV every 3 weeks. The study employs a partial crossover design: Arm 1 receives regular diet with pembrolizumab for cycles 1-3, then crosses over to FMD with pembrolizumab for cycles 4-6; Arm 2 receives FMD with pembrolizumab for cycles 1-3, followed by regular diet thereafter. FMD consists of a 4-day cycle with calorie restriction (fats:carbs:protein ratio of 50:40:10) administered starting on the day of pembrolizumab infusion, followed by transitional diet on day 5, for 3 consecutive cycles. Primary endpoints include feasibility (proportion completing 3 FMD cycles, target ≥70%) and safety. Secondary endpoints include immune-mediated toxicity rates, objective response rate, disease control rate, and 12-month progression-free survival. Exploratory objectives assess FMD impact on metabolic markers (glucose, ketones, IGF-1, IGFBP-1), immune cell populations, body composition via CT imaging, physical function (Short Physical Performance Battery), and quality of life (FACT-L, EORTC QLQ-C30). Enrollment of 33 patients per arm is planned for total of 66 patients. Accrual began in October 2025. Clinical trial information: NCT06671613 , Funded by VA ORD.
No takes yet. Share an insight, caveat, or question.
Aljaras et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: